According to a study published in October in the journal Biomedicine & Pharmacotherapy, a molecule naturally produced by the human body may help protect vision against damage caused by high blood sugar. This finding paves the way for new strategies to prevent diabetic retinopathy. This complication affects more than 22% of people with diabetes worldwide. It occurs when high blood sugar levels cause inflammation and damage neurons and blood vessels in the retina, which can lead to permanent vision loss.
An international research project supported by FAPESP brought together scientists from the Federal University of São Paulo (UNIFESP) and São Paulo State University (UNESP) in Brazil and the University of Colorado Anschutz in the United States.
The group evaluated the Ac2-26 peptide, which is part of an anti-inflammatory protein called Annexin A1, in experimental models that simulate the human eye. The tests were conducted on cell cultures isolated from the retina and on three-dimensional structures that function as "mini-retinas" (organoids), both of which were derived from patients' stem cells.
In the experiments, the peptide acted on several fronts: it reduced inflammation, curbed oxidative stress, and protected mitochondrial function, which generates energy for cells. Together, these actions prevented the death of neurons exposed to high levels of glucose.
"We were able to demonstrate a protective effect on the retina and a potential new strategy for preventing diabetic retinopathy," notes Cristiane Gil , head of the Department of Morphology and Genetics at the School of Medicine (EPM) at UNIFESP and co-author of the article. In a previous study , published in the journal Investigative Ophthalmology & Visual Science, Gil's group had already identified the important role of Annexin A1 in regulating inflammation, as well as changes in blood vessels and glial cells, which are responsible for nourishing and supporting neurons. While these processes were known to be involved in the disease, the peptide had yet to be tested in organoids that simulate diabetic retinopathy.
How vision loss occurs
As diabetic retinopathy progresses, the toxic environment created by oxidative stress and inflammation leads to the premature death of retinal neurons. As this initial damage intensifies, the eye attempts to adapt by producing new blood vessels in a disorderly manner – a process known as angiogenesis. However, these structures are fragile and rupture easily, causing hemorrhages that further exacerbate vision loss.
"The peptide inhibits the signaling pathways that trigger cell death, preventing retinal neurons from dying – something that current treatments for diabetic retinopathy are unable to do. Today, available therapies target a different stage of the disease – the neovascularization phase [formation of new blood vessels] – and often arrive too late to protect the retinal neuron. As is well known, neurons do not regenerate. In other words, when they die, the damage is permanent," explains Rafael André da Silva , a researcher at the University of Colorado Anschutz and first author of the study. He conducted the research during his doctoral studies with support from FAPESP .
For Natalia Vergara, director of the Laboratory of Ocular Development and Translational Technologies at CellSight, University of Colorado Anschutz, the greatest legacy of the study goes beyond simply describing the action of the peptide. The most important aspect was identifying a biological pathway capable of halting diabetic retinopathy and protecting neurons – a discovery that could guide the development of new therapies in the future.
"Diabetic retinopathy isn't merely a vascular disease since retinal neurons suffer damage even in the early stages. By demonstrating that the Ac2-26 peptide helped protect those cells from the effects of high blood glucose and inflammation, including mitochondrial dysfunction, we've opened the door to developing therapies that act directly on neural tissue, which could complement current treatments," says the researcher.
According to Vergara, the collaboration was essential to the discovery. While the Brazilian researchers have years of experience studying Annexin A1 and the Ac2-26 peptide, her laboratory in the United States specializes in human retinal cells and retinal organoids. "By combining those areas of expertise, we were able to test the peptide in human retinal models and raise new scientific questions," she explains.
How to observe protected neurons
The experiments conducted with the organoids made it possible to recreate part of the cellular diversity and layered organization of the human retina in the laboratory, as well as the harmful environment caused by diabetes.
As a result, the team discovered that the Ac2-26 peptide binds to a receptor in the cell called FPR2. This interaction acts as a "brake" on the p38 and NOX4 molecules, which stimulate the production of free radicals. Excessive amounts of these radicals cause oxidative stress and damage the mitochondria, which are the powerhouses of the cells. "By reducing that process, Ac2-26 helps preserve cellular function and increases the survival of retinal neurons under conditions of high glucose and inflammation, which are characteristic of diabetic retinopathy," says Silva.
The study also identified the central role of Müller cells, which extend throughout the retina. As Silva explains, these cells are essential for the eye's defense and nutrition; however, under stress, they overreact. This triggers a process called "gliosis," which amplifies inflammation and ultimately leads to neuronal death. Ac2-26 was able to curb this response by reorganizing the inflammatory environment of the mini-retina.
"Although it was already known that diabetes damages retinal neurons early in the disease, the breakthrough of our study lies in demonstrating, for the first time, a molecule capable of halting that cellular self-destruction in human tissue," says Gil. "That will allow us to advance studies in animal models and in humans so that, in the future, we can develop topical formulations to be applied at the very first signs of diabetic retinopathy."
About São Paulo Research Foundation (FAPESP)
The São Paulo Research Foundation (FAPESP) is a public institution with the mission of supporting scientific research in all fields of knowledge by awarding scholarships, fellowships and grants to investigators linked with higher education and research institutions in the State of São Paulo, Brazil. FAPESP is aware that the very best research can only be done by working with the best researchers internationally. Therefore, it has established partnerships with funding agencies, higher education, private companies, and research organizations in other countries known for the quality of their research and has been encouraging scientists funded by its grants to further develop their international collaboration. You can learn more about FAPESP at www.fapesp.br/en and visit FAPESP news agency at www.agencia.fapesp.br/en to keep updated with the latest scientific breakthroughs FAPESP helps achieve through its many programs, awards and research centers. You may also subscribe to FAPESP news agency at http://agencia.fapesp.br/subscribe.